Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 5;29(8):648-650.
doi: 10.1093/oncolo/oyae136.

Lifileucel: FDA-approved T-cell therapy for melanoma

Mei Li M Kwong  1 , James C Yang  1
Affiliations

Lifileucel: FDA-approved T-cell therapy for melanoma

Mei Li M Kwong et al. Oncologist. .

Abstract

This commentary reports on the history of tumor-infiltrating lymphocytes (TIL) for adoptive cell therapy and where TIL fits into the treatment options for metastatic melanoma.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

Figure 1.
Figure 1.
Patient with extensive liver metastases from melanoma, treated with lymphodepletion, one infusion of autologous TIL, and high-dose IL-2 in 2003. He remains in complete response at his last scan in 2015.
See this image and copyright information in PMC

References

    1. Rosenberg SA, Grimm EA, McGrogan M, et al.. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science. 1984;223(4643):1412-1414. 10.1126/science.6367046 - DOI - PubMed
    1. Yron I, Wood TA Jr, Spiess PJ, Rosenberg SA.. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol. 1980;125(1):238-245. (In eng). - PubMed
    1. Rosenberg SA, Spiess P, Lafreniere R.. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233(4770):1318-1321. 10.1126/science.3489291 - DOI - PubMed
    1. Rosenberg SA, Packard BS, Aebersold PM, et al.. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676-1680. 10.1056/NEJM198812223192527 - DOI - PubMed
    1. Rosenberg SA, Yang JC, Sherry RM, et al.. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550-4557. 10.1158/1078-0432.CCR-11-0116 - DOI - PMC - PubMed